These reports suggest that the prediction of the participation of microRNAs in the regulation of BCL-xL is potentially feasible, however, it is important to confirm if the role of miRNAs is dependent on tissue, and even on the disease, so it is necessary to evaluate the possible participation of miRNAs in the regulation of BCL-xL in hematological malignancies. This evidence concerns the gene BCL2L1 and hematologic disorder.